GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » Capex-to-Operating-Cash-Flow

LifeTech Scientific (HKSE:01302) Capex-to-Operating-Cash-Flow : 0.71 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

LifeTech Scientific's Capital Expenditure for the six months ended in Dec. 2023 was HK$-151.11 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was HK$213.20 Mil.

Hence, LifeTech Scientific's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.71.


LifeTech Scientific Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for LifeTech Scientific's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeTech Scientific Capex-to-Operating-Cash-Flow Chart

LifeTech Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.47 0.78 0.86 0.70

LifeTech Scientific Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.68 1.18 0.69 0.71

Competitive Comparison of LifeTech Scientific's Capex-to-Operating-Cash-Flow

For the Medical Devices subindustry, LifeTech Scientific's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LifeTech Scientific's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where LifeTech Scientific's Capex-to-Operating-Cash-Flow falls into.



LifeTech Scientific Capex-to-Operating-Cash-Flow Calculation

LifeTech Scientific's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-320.135) / 457.253
=0.70

LifeTech Scientific's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-151.106) / 213.2
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LifeTech Scientific  (HKSE:01302) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


LifeTech Scientific Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeTech Scientific (HKSE:01302) Business Description

Traded in Other Exchanges
Address
No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures minimally invasive medical devices for cardiovascular and vascular diseases. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.
Executives
Xie Yuehui 2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Bank Of Communications Trustee Limited 2301 Trustee
Xie Yuehui 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner

LifeTech Scientific (HKSE:01302) Headlines

No Headlines